Baja incidencia de enfermedad linfoproliferativa postrasplante renal con uso predominante de Alemtuzumab / Low incidence of limphoproliferative disease post kidney transplantation with prevalent use of Alemtuzumab
Rev. nefrol. diál. traspl
; 34(1): 21-26, mar 2014. tab
Artigo
em Espanhol
| LILACS
| ID: lil-749980
Biblioteca responsável:
AR444.1
RESUMEN
Introducción:
Se conoce que la incidencia de malignidad es significativamente mayor en los pacientes trasplantados que en la población general. La incidencia de enfermedad linfoproliferativa post trasplante (PTLD) es aproximadamente de 1% a 2% en los receptores de trasplante renal. El objetivo principal de este estudio fue evaluar la incidencia de PTLD en el seguimiento de pacientes trasplantados de riñón entre el 2005 y el 2010. Material yMétodos:
Se tomaron de forma retrospectiva los datos de pacientes trasplantados de riñón entre los años 2005 a 2010 para determinar el número de casos de PTLD según el esquema inductor usado.Resultados:
Se trasplantaron 425 pacientes en el periodo 2005 - 2010. Recibieron alemtuzumab 76.2%, daclizumab 10.7%, basiliximab 3.6% y timoglobulina 2.4%. No recibieron inducción con anticuerpos el 7 %. Durante este tiempo se presentaron 2 casos de PTLD 1 con mieloma múltiple y otro con linfoma. Uno de ellos recibió alemtuzumab y otro timoglobulina.Conclusiones:
En esta cohorte de pacientes donde se usó predominantemente alemtuzumab, la incidencia de PTLD fue más baja que lo reportado en estudios previos.ABSTRACT
Introduction:
It is well known that the incidence of malignancy is significantly higher in transplanted patients than in general population. The incidence of lymphoproliferative disease post-transplantation (PTLD) is approximately of 1% to 2% in kidney transplantation recipients. The main objective of this study was to evaluate the PTLD incidence when monitoring kidney transplanted patients between the years 2005 and 2010. Material andMethods:
Kidney transplanted patients' data was retrospectively taken between the years 2005 to 2010 in order to determine the number of PTLD cases according to the inductor scheme used.Results:
425 patients were transplanted between 2005 and 2010. They received alemtuzumab 76.2%,daclizumab 10.7%, basiliximab 3.6% and thymoglobulin 2.4%. The 7% did not receive antibody induction. During this period 2 cases of PTLD ocurred One with multiple myeloma and the other with lymphoma. One of them had been treated with alemtuzumab and the other with thymoglobulin.Conclusions:
The PTLD incidence in our group, where alemtuzumab was used predominantly as inductor, was very low; this might suggest that alemtuzumab is a medication that does not increase the risk of this kind of neoplasia.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Transplante de Rim
/
Transtornos Linfoproliferativos
/
Anticorpos Monoclonais
Tipo de estudo:
Estudo de incidência
/
Fatores de risco
/
Estudo de rastreamento
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Espanhol
Revista:
Rev. nefrol. diál. traspl
Assunto da revista:
CIRURGIA GERAL
/
Nefrologia
Ano de publicação:
2014
Tipo de documento:
Artigo
País de afiliação:
Colômbia
Instituição/País de afiliação:
Hospital Pablo Tobón Uribe/CO
/
Universidad de Antioquia/CO